This EASL School focusses on the management of real-life complex situations of liver cancer that sometimes are not fully captured by existing guidelines. In this school, students will engage with challenging clinical scenarios, including the treatment of large tumours, tumours in difficult locations, liver dysfunction and portal hypertension, as well as the management of complications from surgery, locoregional and systemic therapies. In addition, the evaluation of progression and treatment decision-making following systemic therapies will be explored. The most recent advances in liver cancer treatment of at different stages will be summarised and applied to clinical cases.

A team of expert clinicians and clinical researchers at Clínica Universidad de Navarra (CUN) in Madrid, dedicated to the management of patients with liver tumours will guide students through clinical decision-making process using real-life cases. Students will first discuss the case in small groups followed by plenary sessions with the wider group and faculty.

School Organisers:

• Delia D’Avola
• Paloma Sangro
• Manuel de la Torre

Please note that the programme is subject to change, and will be updated continuously up to the school event.

• To describe adjuvant and neoadyuvant therapies available to improve surgical outcomes of HCC.
• To analyze and question inclusion features for liver transplantation and local therapies such as selective internal radiation therapy (SIRT) in the era of immunotherapy.
• To explain the role of liver function in the treatment of HCC.
• To expose the tumour responses to different treatment strategies.
• To resume immunotherapy toxicities and their management.

• Gain knowledge regarding the use of bridging and down-staging techniques for patients with large or multiple primary liver tumours.
• Improve the decision-making for the treatment of liver cancer in patients with liver dysfunction and portal hypertension.
• Increase the knowledge regarding the use of immunotherapy and its combination for the treatment of HCC and CC) and managing toxicity.
• Learn how to assess and manage tumour progression after systemic therapies.
• Empower treatment decision in oligometastatic disease, oligoprogression or treatment of residual disease.

• To get updated on the most-recent advances in the multidisciplinary approach for the treatment of primary liver cancer.
• Answering questions regarding management of challenging cases from experts in the treatment of liver cancer.
• Networking with different specialists involved in the treatment of liver cancer.

• Hepatologists
• Interventional radiologists
• Oncologists
• Liver Surgeons